Oncolytic virus therapy for prostate cancer
- 20 December 2009
- journal article
- review article
- Published by Wiley in International Journal of Urology
- Vol. 17 (1) , 20-30
Abstract
The use of replication-competent viruses that can selectively replicate in and destroy neoplastic cells is an attractive strategy for treating cancer. Various oncolytic viruses have been taken to clinical trials since a recombinant virus was first applied to cancer patients a decade ago. The concept of the therapy is simple: infectious virus kills the host cancer cells in the course of viral replication. It is important, however, that the virus does not harm the surrounding normal tissue. Oncolytic viruses can be classified largely into two groups: DNA viruses genetically engineered to achieve cancer specificity (e.g. adenovirus, herpes simplex virus and vaccinia) and RNA viruses of which human is not the natural host (e.g. Newcastle disease virus and reovirus). Prostate cancer has always been one of the major targets of oncolytic virus therapy development. The result of six clinical trials for prostate cancer has been published and several trials are now going on. Forty-eight of 83 (58%) patients evaluated in the phase I studies demonstrated a >25% decrease in serum prostate-specific antigen level without evidence of severe toxicities. The result shows the oncolytic virus therapy is promising toward clinical application. Here, we review the recent advances in the field and summarize the results from clinical trials.Keywords
This publication has 58 references indexed in Scilit:
- Erratum: Anticancer oncolytic activity of respiratory syncytial virusCancer Gene Therapy, 2009
- Prostate‐specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancerThe Prostate, 2009
- Early Steps of the Virus Replication Cycle Are Inhibited in Prostate Cancer Cells Resistant to Oncolytic Vesicular Stomatitis VirusJournal of Virology, 2008
- A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced CancerClinical Cancer Research, 2008
- Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963Journal of Clinical Investigation, 2007
- Five-year Follow-up of Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy for Treatment of Prostate CancerMolecular Therapy, 2007
- Selective Intratumoral Amplification of an Antiangiogenic Vector by an Oncolytic Virus Produces Enhanced Antivascular and Anti-tumor EfficacyMolecular Therapy, 2006
- Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificityCancer Gene Therapy, 2005
- Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancerThe Prostate, 2004
- Oncolytic Viral Therapy for Human Prostate Cancer by Conditionally Replicating Herpes Simplex Virus 1 Vector G207Japanese Journal of Cancer Research, 2000